Efficacy of tegaserod for functional constipation in Chinese subjects: A randomized double-blind controlled trial in a single centre

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 4, 2007, Pages 463-469

  On Chan, A O ^a   Mo Hui, W ^a   Leung, G ^a   Hu, W H C ^a   Lam, S K ^a   Wong, B C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TEGASEROD;

ABDOMINAL BELCHING; ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ADULT; ANKLE EDEMA; ARTICLE; BLOATING; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DEFECATION HABIT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FECES ANALYSIS; FEMALE; HEMORRHOID; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE; VOMITING;

ADULT; CHINA; CHRONIC DISEASE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33846587919     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03230.x     Document Type: Article

References (22)

1. Talley NJ, O'Keefe EA, Zinsmeister AR, et al. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterol 1992; 102: 895-901.
2. Cheng C, Chan AO, Hui WM, et al. Coping strategies, illness perception, anxiety, and depression of patients with idiopathic constipation: a population-based study. Aliment Pharmacol Ther 2003; 18: 319-26.
3. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorder. Gastroenterol 2006; 130: 1480-91.
4. Buchheit KH, Buhl T. Prokinetic benzamides stimulate peristaltic activity in the isolated guinea pig ileum by activation of 5-HT4 receptors. Eur J Pharmacol 1991; 205: 203-8.
5. Buchheit KH, Gamse R, Pfannkuche HJ. SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum. Pharmacol 1992; 345: 387-393.
6. Grider JR, Foxx-Orenstein AE, Jin JG. 5 Hydroxy-tryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterol 1998; 115: 370-80.
7. Grider JR, Kuemmerle JF, Jin J-G. 5-HT released by mucosal stimulation acts via 5 HT4 receptors to release the sensory transmitter CGRP and initiate the peristaltic reflex. Gastroenterol 1994; 106: A506.
8. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. The peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine is mediated by distinct mucosal 5-HT receptors. Gastroenterol 1995; 108: A600.
9. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 Stimulates Canine Colonic Motility and Transit In Vivo. J Pharmacol Exp Ther 1997; 280: 1270-6.
10. Degen L., Matzinger D., Merz M., Appel-Dingemanse S., Maecke H., Beglinger C. Tegaserod (HTF 919), a 5-HT4 receptor partial agonist accelerates gastrointestinal (GI) transit. Gastroenterol 2000; 118(Suppl. 2): A845; 4436.
11. Prather C., Camilleri M., Zinsmeister A., McKinzie S., Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterol 2000; 118: 463-8.
12. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004; 2: 796-805.
13. Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100: 362-72.
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
15. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
16. Chaussade S, Khyari A, Roche H, et al. Determination of total and segmental colonic transit time in constipated patients. Results in 91 patients with a new simplified method. Dig Dis Sci 1989; 34: 1168-72.
17. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterol 1987; 92: 40-47.
18. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
19. Müller-Lissner SA, Fumagalli I, Bardhan K, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
20. Novick J, Miner P, Kranse R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
21. Rao SS, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol. 2005; 100: 1605-15.
22. Ding JH, Fu CG, Zhao RH, Meng RG. Serotonin transporter gene polymorphism in slow transit constipation. Zhonghua Wei Chang Wai Ke Za Zhi. 2006; 9: 328-30.